OA11049A - Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound - Google Patents

Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound Download PDF

Info

Publication number
OA11049A
OA11049A OA9900105A OA9900105A OA11049A OA 11049 A OA11049 A OA 11049A OA 9900105 A OA9900105 A OA 9900105A OA 9900105 A OA9900105 A OA 9900105A OA 11049 A OA11049 A OA 11049A
Authority
OA
OAPI
Prior art keywords
compound
activity
platelet
pharmaceutical composition
platelet aggregation
Prior art date
Application number
OA9900105A
Other languages
English (en)
Inventor
Alain H Curaudeau
Christopher T Dunwiddie
Robert J Leadley
Mark H Perrone
Andre Uzan
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21861879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11049(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of OA11049A publication Critical patent/OA11049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA9900105A 1996-11-27 1999-05-19 Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound OA11049A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3187896P 1996-11-27 1996-11-27

Publications (1)

Publication Number Publication Date
OA11049A true OA11049A (en) 2002-02-18

Family

ID=21861879

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900105A OA11049A (en) 1996-11-27 1999-05-19 Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound

Country Status (28)

Country Link
US (2) US6103705A (ja)
EP (1) EP0946185B2 (ja)
JP (1) JP4498471B2 (ja)
KR (1) KR100512671B1 (ja)
CN (1) CN1121224C (ja)
AP (1) AP1390A (ja)
AT (1) ATE283062T1 (ja)
AU (1) AU754936B2 (ja)
BG (1) BG64542B1 (ja)
BR (1) BR9713141A (ja)
CA (1) CA2272317C (ja)
CZ (1) CZ298552B6 (ja)
DE (1) DE69731763T3 (ja)
DK (1) DK0946185T4 (ja)
EA (1) EA002475B1 (ja)
ES (1) ES2230624T5 (ja)
HK (1) HK1023504A1 (ja)
HU (1) HUP9903496A3 (ja)
IL (1) IL129877A (ja)
NO (1) NO327740B1 (ja)
OA (1) OA11049A (ja)
PL (1) PL189116B1 (ja)
PT (1) PT946185E (ja)
SI (1) SI0946185T2 (ja)
SK (1) SK286024B6 (ja)
UA (1) UA63929C2 (ja)
WO (1) WO1998023279A1 (ja)
ZA (1) ZA9710691B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754936B2 (en) * 1996-11-27 2002-11-28 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
WO2000029019A1 (en) * 1998-11-18 2000-05-25 G.D. Searle & Co. Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
HUP0201712A3 (en) * 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
EP1315539A2 (en) * 2000-09-08 2003-06-04 Leo Pharma A/S Antithrombotic compositions
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
US20040171819A1 (en) * 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP5137228B2 (ja) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
KR100601429B1 (ko) * 2004-07-09 2006-07-14 주식회사 대우일렉트로닉스 기계식 전자렌지의 댐퍼 구동회로
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
CN101783857B (zh) * 2009-05-12 2011-11-30 上海海事大学 一种基于fpga在高分辨率成像系统中的图像矩阵化预处理方法
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2508892A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
RU2554803C1 (ru) * 2014-06-26 2015-06-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики развития послеоперационных венозных тромбоэмболических осложнений у пациентов с колоректальным раком

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766167A (en) * 1971-03-26 1973-10-16 Research Corp Orally active anticoagulant
SE449753B (sv) * 1978-11-06 1987-05-18 Choay Sa Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav
FR2440376A1 (fr) * 1978-11-06 1980-05-30 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
FR2478646A2 (fr) * 1980-03-20 1981-09-25 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
DE3265781D1 (en) * 1981-05-21 1985-10-03 Akzo Nv New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions
US4533549A (en) * 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
DK196886D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US4833155A (en) * 1986-11-25 1989-05-23 Syntex (U.S.A.) Inc. 3-(ω-(3,5,-di-t-butyl-4-hydroxyphenyl)-alkanoyl)pyrroles, and anti-inflammatory uses thereof
EP0275748B1 (fr) * 1986-12-15 1992-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés peptidiques et leur application notamment en thérapeutique
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
IT1234508B (it) * 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH05500954A (ja) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド 抗血栓性ペプチド及び疑似ペプチド
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
IL99539A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
WO1992013117A1 (en) * 1991-01-24 1992-08-06 Aerojet-General Corporation Electrochemical desensitization process
CZ232593A3 (en) * 1991-05-02 1994-07-13 Yeda Res & Dev Pharmaceutical preparation for preventing and/or therapy of pathological states
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
JPH08508498A (ja) * 1993-03-29 1996-09-10 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 血小板糖タンパク質▲ＩＩ▼ｂ／▲ＩＩＩ▼ａの阻害剤として有用な環状化合物
PT812205E (pt) * 1993-10-15 2001-08-30 Rhone Poulenc Rorer Pharma Peptidos e pseudo-peptidos antitromboticos de azacicloalqilalcacoilo
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
WO1997035592A1 (en) * 1996-03-28 1997-10-02 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
AU754936B2 (en) * 1996-11-27 2002-11-28 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound

Also Published As

Publication number Publication date
EP0946185A4 (en) 2001-06-27
EP0946185A1 (en) 1999-10-06
KR20000057265A (ko) 2000-09-15
SI0946185T1 (en) 2005-06-30
AU5454698A (en) 1998-06-22
SI0946185T2 (sl) 2010-08-31
HUP9903496A2 (hu) 2000-10-28
EP0946185B2 (en) 2010-05-05
UA63929C2 (uk) 2004-02-16
HK1023504A1 (en) 2000-09-15
ATE283062T1 (de) 2004-12-15
US6103705A (en) 2000-08-15
WO1998023279A1 (en) 1998-06-04
DE69731763T2 (de) 2005-06-30
IL129877A (en) 2004-08-31
AU754936B2 (en) 2002-11-28
NO992555L (no) 1999-05-27
HUP9903496A3 (en) 2001-03-28
US20020032214A1 (en) 2002-03-14
DE69731763T3 (de) 2010-12-30
EP0946185B1 (en) 2004-11-24
BG103372A (en) 2000-01-31
KR100512671B1 (ko) 2005-09-07
PL189116B1 (pl) 2005-06-30
DE69731763D1 (de) 2004-12-30
AP9901517A0 (en) 1999-06-30
ES2230624T3 (es) 2005-05-01
CN1121224C (zh) 2003-09-17
NO992555D0 (no) 1999-05-27
CA2272317C (en) 2001-01-30
BR9713141A (pt) 2000-02-08
PT946185E (pt) 2005-02-28
EA199900499A1 (ru) 2000-04-24
NO327740B1 (no) 2009-09-14
AP1390A (en) 2005-04-15
ZA9710691B (en) 1998-06-12
JP2001506603A (ja) 2001-05-22
SK67399A3 (en) 2000-07-11
EA002475B1 (ru) 2002-06-27
CZ298552B6 (cs) 2007-10-31
DK0946185T4 (da) 2010-08-30
CN1238693A (zh) 1999-12-15
CZ174299A3 (cs) 1999-09-15
SK286024B6 (sk) 2008-01-07
DK0946185T3 (da) 2005-03-21
ES2230624T5 (es) 2010-10-25
JP4498471B2 (ja) 2010-07-07
IL129877A0 (en) 2000-02-29
BG64542B1 (bg) 2005-07-29

Similar Documents

Publication Publication Date Title
AP1390A (en) Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound.
Magnani Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction
De Swart et al. Kinetics of intravenously administered heparin in normal humans
Collins Jr et al. The effects of operative stress on the coagulation profile
CZ20013757A3 (cs) Farmaceutická kompozice obsahující inhibitor trombinu o nízké molekulové hmotnosti a jeho prekuzor
RU2290195C1 (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
McCrirrick et al. Haemodynamic effects of tracheal compared with intravenous adrenaline
Köhler Aerosolized heparin
JPH08208504A (ja) 抗血栓および血栓溶解療法と組み合わせて適用する治療法としてのｖＷＦ−含有濃縮物の使用
JP3838680B2 (ja) 抗凝血物質に対する解毒剤として用いるのに適した医薬およびその使用
EA035358B1 (ru) Способ, набор и комбинация для лечения субъекта с симптомами инсульта или острого инфаркта миокарда
CN103908459B (zh) 三七皂苷Ft1的医药用途
Rebello et al. Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs
MXPA99005008A (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
Bunce et al. Platelet function in patients receiving enprostil
Verstraete et al. Report on a preparation of pectin: Sangostop®
Becker et al. The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration
JPH11100322A (ja) 新規虚血・再灌流障害抑制剤
SAKURAGAWA HIROYUKI ARAI TERUO MIYAKAWA